Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ayr Wellness Inc C.AYR.A

Alternate Symbol(s):  AYRWF

AYR Wellness Inc. is a vertically integrated multi-state cannabis operator in the United States. The Company operates simultaneously as a retailer with more than 90 licensed dispensaries and a house of cannabis consumer packed goods (CPG) brands. It is a cultivator, manufacturer and retailer of cannabis products and branded CPG, and is engaged in the manufacture, possession, use, sale, or distribution of cannabis and/or holds licenses in the adult-use and/or medicinal cannabis marketplace in the States of Massachusetts, Nevada, Pennsylvania, Florida, New Jersey, Ohio, Illinois, and Connecticut. The Company’s portfolio of CPG brands includes Kynd, Origyn Extracts, Levia, STiX Preroll Co., Secret Orchard, and Entourage, among others. It owns and operates a chain of cannabis retail stores under various brand names. The Company distributes and markets its products to Company-owned retail stores and to third-party licensed retail cannabis stores throughout its operating footprint.


CSE:AYR.A - Post by User

Post by Humaniston Mar 13, 2021 10:33pm
231 Views
Post# 32794160

CORRETION: AYR OUTLOOK FOR 2021/2022

CORRETION: AYR OUTLOOK FOR 2021/2022
CORRECTION -- Ayr Wellness Provides Outlook for 2022
March 13, 2021 - 1:15 PM EST
 
 
TORONTO, March 13, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Friday, March 12 th by Ayr Wellness Inc. (CSE:AYR.A, OTCQX:AYRWF),

please note that in the last bullet of the Florida section, the Company expects to reach annual retail revenues of roughly 4 million per store in 2022, in-line with the state average.


The corrected release follows:
Ayr Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“Ayr” or the “Company”), a vertically-integrated cannabis multi-state operator (MSO), on March 11, 2021 in connection with its fourth quarter and year-end 2020 results, provided an outlook for 2022, which included target revenues of US$725 million and Adjusted EBITDA (see “Non-IFRS Measures below) of US$325 million. As 2021 is expected to be a transitional year, no outlook is being provided for 2021.
In developing the guidance set forth above, Ayr made the following assumptions and relied on the following factors and considerations (as well as those referred to under “Forward-Looking Information” below):

  • The targets are subject to the timing of pending M&A transactions:
    • Arizona and Ohio will close by the end of Q1 2021
    • New Jersey will close by the end of Q3 2021
       
  • The targets are subject to the timing of on-line dates for cultivation and manufacturing capacity as well as retail store openings:
     
  • Pennsylvania:
  • 45,000 sq ft of cultivation and manufacturing capacity will come on-line in Q2 2021, followed by an additional 38,000 in Q3 2021 and an additional cultivation expansion in Q3 2022
  • Four additional retail locations will open in the second half of 2021, bringing total store count to six
     
  • Arizona: 80,000 sq ft of additional cultivation and manufacturing capacity will come on-line in Q4 2021
     
  • 76,000 sq ft of additional cultivation and manufacturing capacity will come on-line in Q1 2022
  • Adult-use sales will begin in Q1 2022
     
  • Three adult-use retail locations in Greater Boston will be approved to open and will open by Q1 2022
  • 93,000 sq ft of additional cultivation and manufacturing capacity will come on-line in Q2 2022
     
  • 42 retail locations in Florida by the end of 2021
  • Steady, gradual improvement in cultivation yields in Florida and retail throughput in 2021 to reach annual retail revenues of roughly $4 million per store in 2022, in-line with the state average
     
  • 58,000 sq ft of cultivation and manufacturing capacity will come on-line in Q3 2022
  • New Jersey:
  • Massachusetts:
  • Florida:
  • Ohio:
Note: 2022 guidance is based on IFRS accounting standards. Ayr Wellness expects to transition to US GAAP beginning in Q1 2021 and any impact on the 2022 outlook related to the change in accounting standards is planned to be discussed in detail on the Q1 2021 conference call.

The Ayr Wellness fourth quarter and full year 2020 results press release dated March 11, 2021 can be found here . The conference call is available for replay here .
A telephonic replay of the conference call is through March 18, 2021.
Toll-free replay number: (855) 859-2056
International replay number: (404) 537-3406
Replay ID: 2287507

Financial Statements
Certain financial information reported in this news release is extracted from Ayr’s Consolidated Financial Statements for the year ended December 31, 2020. Ayr files its annual financial statements on SEDAR. All such financial information contained in this news release is qualified in its entirety by reference to such financial statements.

Definition and Reconciliation of Non-IFRS Measures
The Company reports certain non-IFRS measures that are used to evaluate the performance of its businesses and the performance of their respective segments, as well as to manage their capital structures. As non-IFRS measures generally do not have a standardized meaning, they may not be comparable to similar measures presented by other issuers. Securities regulators require such measures to be clearly defined and reconciled with their most comparable IFRS measure.
The Company references non-IFRS measures and cannabis industry metrics in this document and elsewhere. Non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these are provided as additional information to complement those IFRS measures by providing further understanding of the results of the operations of the Company from management’s perspective.

Accordingly, these measures should not be considered in isolation, nor as a substitute for analysis of the Company’s financial information reported under IFRS. Non-IFRS measures used to analyze the performance of the Company’s businesses include “Adjusted EBITDA.”
The Company believes that these non-IFRS financial measures provide meaningful supplemental information regarding the Company’s performances and may be useful to investors because they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making. These financial measures are intended to provide investors with supplemental measures of the Company’s operating performances and thus highlight trends in the Company’s core businesses that may not otherwise be apparent when solely relying on the IFRS measures.

Adjusted EBITDA
“Adjusted EBITDA” represents income (loss) from operations, as reported, before interest and tax, adjusted to exclude non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, the adjustments for the accounting of the fair value of biological assets, and further adjusted to remove acquisition related costs.

A reconciliation of how Ayr calculates Adjusted EBITDA is provided below. Additional reconciliations of Adjusted EBITDA and other disclosures concerning non-IFRS measures is provided in our MD&A for the year ended December 31, 2020. As well, the Company reminds you that Adjusted EBITDA is a non-IFRS measure.

wellness.com .
About Ayr Wellness Inc.
Ayr is an expanding vertically integrated, U.S. multi-state cannabis operator, focused on delivering the highest quality cannabis products and customer experience throughout its footprint. Based on the belief that everything starts with the quality of the plant, the Company is focused on superior cultivation to grow superior branded cannabis products. Ayr strives to enrich consumers’ experience every day through the wellness and wonder of cannabis.

Ayr’s leadership team brings proven expertise in growing successful businesses through disciplined operational and financial management, and is committed to driving positive impact for customers, employees and the communities they touch. For more information, please visit ayrwellness.com.
Company Contact:
Megan Kulick
Head of Investor Relations
T: (646) 977-7914
Email: IR@ayrwellness.com .
Investor Relations Contact:
Sean Mansouri, CFA or Cody Slach
Gateway Investor Relations
T: (949) 574-3860
Email: IR@ayrwellness.com
Ayr Wellness Inc. (formerly, Ayr Strategies Inc.)
Unaudited Condensed Interim Consolidated Adjusted EBITDA Reconciliation
(Expressed in United States Dollars)

  Three Months ended December 31,   Year ended December 31,
  2020   2019   2020   2019
(Loss) Income from operations (2,052,353 )   (16,898,258 )   16,117,080     (37,467,213 )
               
Non-cash items accounting for biological assets and inventory              
Incremental costs to acquire cannabis inventory in business combination -     3,764,678     -     3,764,678  
Fair value adjustment on sale of inventory 12,971,862     4,838,814     34,147,938     18,272,212  
Unrealized gain on biological asset transformation (4,115,927 )   (1,765,527 )   (48,690,657 )   (10,108,105 )
  8,855,935     6,837,965     (14,542,719 )   11,928,785  
               
Interest 258,077     295,630     986,870     295,630  
Depreciation and amortization (from statement of cash flows) 5,017,319     4,511,734     18,436,700     10,310,237  
Acquisition costs 1,890,428     724,139     2,945,194     5,847,800  
Stock-based compensation expense, non-cash 5,207,204     13,296,643     31,156,759     28,879,225  
Other non-operating 1 182,343     472,326     1,089,912     1,105,694  
  12,555,371     19,300,472     54,615,435     46,438,586  
               
Adjusted EBITDA (non-IFRS) 19,358,953     9,240,179     56,189,796     20,900,158  
               
Other non-operating adjustments made to exclude the impact of non-recurring items            
               
https://www.globenewswire.com/newsroom/ti?nf=ODE4OTYxNCM0MDYyODkyIzIxODQzOTU=


Source: GlobeNewswire (March 13, 2021 - 1:15 PM EST)

News by QuoteMedia
www.quotemedia.com
 

<< Previous
Bullboard Posts
Next >>